RecruitingNCT07139418
The Clinical Significance of Examining Metastatic Lymph Nodes in Individual Gastric Mesenteries in the Patients With Gastric Cancer Undergoing Gastrectomy
The Clinical Significance of Examining Metastatic Lymph Nodes in Respective Gastric Mesenteries in the Gastric Cancer Patients Who Received D2 Lymphadenectomy Plus Complete Mesogastric Excision
Sponsor
Jichao Qin
Enrollment
400 participants
Start Date
Oct 7, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims to examine the predictive value of metastatic gastric mesenteries, which contains metastatic lymph node, in 6 gastric mesenteries; and importantly, to further evaluate the relationship between the number of metastatic gastric mesenteries and prognosis in the gastric cancer patients who received D2+complete mesogastric excision (CME).
Eligibility
Min Age: 18 YearsMax Age: 85 Years
Inclusion Criteria6
- Aged older than 18 years and younger than 85 years
- Primary gastric adenocarcinoma confirmed by preoperative pathology result
- cT2-4aN0-3M0 at preoperative evaluation according to the American Joint 8 Committee on Cancer (AJCC) Cancer Staging Manual 8th Edition
- Patients who received gastrectomy with D2 lymphadenectomy plus complete mesogastric excision
- American Society of Anesthesiologists (ASA) class I, II, or III
- Written informed consent
Exclusion Criteria8
- Negative preoperative biopsy
- Too late tumour stage or metastasis (cT4b/M1)
- BMI\>30 kg/m2
- Total gastrectomy or proximal gastrectomy
- previous neoadjuvant chemotherapy or radiotherapy
- Previous upper abdominal surgery
- Combined with other malignant diseases
- Reject operation
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07139418
Related Trials
The Vanguard Study: Testing a New Way to Screen for Cancer
NCT0699589836 locations
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
NCT068827463 locations
National Cancer Institute "Cancer Moonshot Biobank"
NCT04314401152 locations
Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer
NCT064082201 location
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT073157501 location